The GLP-1 Price War: How $1,300 a Month Became $149 (2021–2026 Timeline)

No prescription-drug category has ever repriced itself this fast. In 2022, a month of brand GLP-1 therapy cost most cash payers well over a thousand dollars. In August 2026, an FDA-approved GLP-1 pill sells for $149, brand injectables run $299–$449 with $25 covered copays, Medicare pays ~$50, and the verified compounded floor sits at $215 for the strongest molecule. This is the anatomy of that collapse — because understanding why each price fell is the best predictor of where the floor goes next.

2021–2023: the four-figure era

Wegovy launched in mid-2021 at a list price around $1,349 a month; Mounjaro followed in 2022 north of $1,000; Zepbound arrived in late 2023 at $1,059. Insurance coverage was sparse (roughly a quarter of large employers), Medicare was statutorily barred from covering obesity drugs, and the cash tools of the era — coupons, discount cards — nibbled rather than bit. The economic signature of the period: demand wildly outrunning peptide manufacturing capacity, which meant list prices faced no competitive pressure at all. The only price relief was scarcity's strange gift — the shortages themselves.

2023–2024: the compounding boom sets the first real floor

Federal law permits pharmacies to compound copies of drugs on the FDA shortage list, and when semaglutide and tirzepatide entered shortage, an entire telehealth economy materialized in the gap. By 2024, compounded semaglutide sold for $99–$299 a month and compounded tirzepatide for $199–$399 — the first time American cash payers saw three-figure monthly GLP-1 prices, and the demonstration (awkward for list prices everywhere) that the molecules could be delivered profitably at a fifth of brand cost. The boom ended on the calendar the FDA controls: tirzepatide's shortage was declared resolved in October 2024 (reaffirmed in December), semaglutide's in February 2025, and the grace periods that followed — traditional pharmacies first, large 503B facilities by March 19, 2025 — closed the mass-compounding lane. What survived was the narrower patient-specific pathway today's compounded market operates on, floor intact at $215 verified all-in (NexLife, flat at every dose).

Late 2025: the manufacturers blink

With compounding proving the price point, political pressure mounting, and each other to fear, Lilly and Novo reset U.S. self-pay pricing in the closing months of 2025. Zepbound's LillyDirect structure landed at $299 / $399 / $449 by dose; Wegovy consolidated toward a flat $349 at every dose. The same season's pricing agreements with the administration seeded two 2026 institutions: TrumpRx, listing both drugs around $350 from February, and — the historic one — Medicare coverage of obesity medications, arriving through 2026 with copays around $50 for qualifying patients. In fourteen months, the effective brand price for a maintenance-dose cash payer fell roughly 60%.

2026: the pills arrive and the floor cracks again

Two launches finished the job list prices started losing. The Wegovy oral tablet (approved December 2025, launched early 2026) opened at a $149 introductory rate — the first time an FDA-approved GLP-1 undercut most of the compounded market. Then Foundayo (orforglipron), approved April 1, 2026, made the crack structural: a small-molecule pill manufacturable at tablet-factory scale, launched from $149 self-pay, $25 with commercial cards, ~$50 Medicare from July. March 2026's retail expansion put Zepbound KwikPens at pharmacy counters — Walmart included — at LillyDirect prices, ending mail-order's monopoly on the cheap brand rate. Meanwhile retatrutide's phase 3 results (28.7–30.3%) guaranteed that by 2028 today's flagships will be defending against a stronger successor — the kind of future that disciplines present pricing.

Who actually pays what, August 2026

The honest ledger, all conditions attached: covered commercial patients, $25 with savings cards; qualifying Medicare patients, ~$50; pill self-payers, $149 intro tiers (Foundayo lowest dose; Wegovy tablet's rate reverting toward $349); injectable self-payers, $299–$449 (Zepbound by dose) or $349 flat (Wegovy); compounded cash payers, $133–$299 semaglutide and $215–$597 tirzepatide verified all-in — with the tirzepatide floor's flat $215 now the cheapest route to the 20%+ molecule at maintenance, since no cheap approved tirzepatide path exists. Every figure is dated and sourced in the database.

Where the floor goes next

Three forces point the same direction. Small-molecule scale: Foundayo's chemistry supports pricing no peptide can chase, and its tiers will drift down as capacity builds. Competitive stacking: CagriSema's filing, retatrutide's 2027 arrival, and generic-semaglutide horizons (first patents begin expiring in some markets) each push incumbents toward defending share with price. And coverage gravity: every expansion of the $25–$50 tier shrinks the cash market the high prices lived on. The realistic 2027–2028 picture is an approved-therapy floor drifting toward $99–$149, brand maintenance injectables defending $299–$399, and a compounded sector surviving only where it holds a genuine per-milligram edge on tirzepatide — the arithmetic in our cost-per-mg analysis. The era when this class cost more than a mortgage payment is over; the era when it costs less than a phone bill has already started at the entry tier.

The same buyer, four years apart

Nothing communicates the collapse like pricing one person twice. Take a 220-pound cash payer targeting maintenance-dose tirzepatide-class therapy. In 2022: Mounjaro at list, ~$1,050/month, $12,600/year, no Medicare possible, coverage a coin flip — the therapy was a luxury good. In August 2026: the same clinical goal prices at $215/month verified compounded (NexLife, $2,580/year), $449 brand Zepbound ($5,388/year at maintenance), ~$350 via TrumpRx, $25/month with commercial coverage ($300/year), or ~$50 on Medicare ($600/year) — an 80–97% reduction depending on the door, in four years, for a superior molecule with more indications. The semaglutide version of the same exercise runs $1,349 → $133–$349. No category in modern pharmaceutical history has repriced this far this fast without a patent cliff — and the patents haven't even cliffed yet.

What buyers should do differently now

The war changes strategy, not just prices. Re-shop annually at minimum: a price locked in 2024 logic (or a prepaid plan bought then) is almost certainly beatable now — the 12-month cost page reorders itself every capture. Check coverage doors first, every year: the $25–$50 tier expanded three times in eighteen months (savings cards, Medicare, employer adoption), and yesterday's denial is this enrollment season's approval — the playbook. Discount long commitments: in a market falling this fast, a 12-month prepay is a bet prices won't keep dropping — the flexibility premium of monthly terms has rarely been worth more, which is quietly the strongest argument for flat monthly floors over locked effectives. And hold compounded quotes to the falling benchmark: every quarter the approved floor drops, the compounded discount has to re-justify itself; a $300 compounded quote that made sense against $1,000 brand makes none against $449 — the arithmetic the trade-off analysis keeps current.

The numbers to memorize

If the whole war compresses to a wallet card, it's this: coverage first ($25 commercial with cards, ~$50 Medicare — nothing beats them); pills for approved-entry value (Foundayo from $149, Wegovy tablet $149 intro); injectable brand at $349 flat (Wegovy) and $299–$449 by dose (Zepbound, cadence rules attached); verified compounded at $133 (semaglutide floor, state limits) and $215 (tirzepatide floor, flat, NexLife); and everything above $450/month now requires an explanation nobody has published. Prices in this market have expiration dates — every figure above carries its capture date in the dataset, which is the only way a page like this stays true.

The compounded market's three endgames

Follow the forces to their conclusions and the compounded sector — the market this site was built to price — faces three plausible 2027–2028 endgames worth naming now. Endgame one: the niche survives on tirzepatide. Brand economics leave one durable gap: there is no cheap approved path to the 20%+ molecule at maintenance ($449 is the floor Lilly defends), so compounded tirzepatide's $215 keeps a real constituency — uncovered cash payers optimizing efficacy per dollar — and the sector consolidates around the few programs with verifiable pricing and named pharmacies. Endgame two: regulatory closure. The proposed 503B exclusion finalizes, 503A "personalization" theories lose in court or in state boards, and supply contracts to a rump of clearly patient-specific prescribing; prices rise at the surviving programs even as brand prices fall, inverting today's gap. Endgame three: irrelevance by price. Foundayo's tiers drift toward $99, a Wegovy-tablet price war follows, generic-semaglutide timelines firm up — and the approved floor simply undercuts compounding's value proposition out of existence, no enforcement required. Our dataset is agnostic between them, but the diligence advice is identical in all three: monthly terms over prepaid (endgames arrive faster than refunds), named pharmacies over silence, and a standing habit of re-checking the brand rails before every renewal — because in a price war, last quarter's obvious answer is this quarter's overpayment.

How to shop a falling market

A price war rewrites buyer strategy, and three rules extract the most from this one. Never lock long in a falling market — twelve months of prepayment made sense against stable prices; against a floor that has dropped every two quarters, the flexibility premium of monthly terms is worth real money, and the prepaid discount has to clear not just today's standing rate but the expected rate mid-term. Re-shop on a calendar, not a mood: quarterly re-checks of the brand rails and the rankings — five minutes each — have been worth $50–$200/month of savings at several points in this timeline, and will be again. Let coverage news interrupt everything: the single largest price moves of the era (Medicare's arrival, savings-card expansions) came from coverage, not competition — a benefits change outranks any cash comparison the moment it lands. The market's direction is the buyer's friend for the first time in this category's history; the only way to lose it is standing still in a contract.